Skip to content
PeptideTech
Cart

Home / Research library / Nefiracetam Powder

Nootropics

Nefiracetam Powder: molecular data, studies & sources

Nefiracetam Powder is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C14H18N2O2
Molecular weight (MW)
246.30 g/mol
PubChem compound ID
71157
Record title
Nefiracetam

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 71157 · retrieved 2026-09-21

2D molecular structure for Nefiracetam Powder, PubChem CID 71157
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
InChIKey
NGHTXZCKLWZPGK-UHFFFAOYSA-N
SMILES
CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O
Machine-readable PubChem source
Calculated molecular descriptors
Monoisotopic (exact) mass246.1368 Da
Heavy atoms18
Hydrogen-bond donors1
Hydrogen-bond acceptors2
Rotatable bonds3
Topological polar surface area49.4 Ų
Calculated logP (Crippen)1.86
Rings2
Stereocenters0
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Nefiracetam as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

1 registered study matched.

StudyPhase · statusConditionsSponsor · size
Nefiracetam Therapy of Alzheimer's Type DementiaNCT00001933 · start 1999-07Phase 2CompletedAlzheimer's DiseaseNational Institute of Neurological Disorders and Stroke (NINDS)50 participants

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    Double-blind randomized treatment of poststroke depression using nefiracetam.

    Robinson RG, Jorge RE, Clarence-Smith K et al. · The Journal of neuropsychiatry and clinical neurosciences · 2008

    PMID 18451188 · DOI: 10.1176/jnp.2008.20.2.178

  2. Human study · PubMed trial index

    A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy.

    Starkstein SE, Brockman S, Hatch KK et al. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2016

    PMID 26915605 · DOI: 10.1016/j.jstrokecerebrovasdis.2016.01.032

  3. Human study · PubMed trial index

    Double-blind treatment of apathy in patients with poststroke depression using nefiracetam.

    Robinson RG, Jorge RE, Clarence-Smith K et al. · The Journal of neuropsychiatry and clinical neurosciences · 2009

    PMID 19622685 · DOI: 10.1176/jnp.2009.21.2.144

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Review · secondary evidence

    Nefiracetam. DM 9384, DZL 221, Translon.

    · Drugs in R&D · 2002

    PMID 12099172 · DOI: 10.2165/00126839-200203030-00017

  2. Preclinical / laboratory research

    Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons.

    Huang CS, Ma JY, Marszalec W et al. · Neuropharmacology · 1996

    PMID 9014140 · DOI: 10.1016/s0028-3908(96)00074-3

  3. Preclinical / laboratory research

    Nefiracetam improves Morris water maze performance following traumatic brain injury in rats.

    DeFord SM, Wilson MS, Gibson CJ et al. · Pharmacology, biochemistry, and behavior · 2001

    PMID 11509223 · DOI: 10.1016/s0091-3057(01)00559-7

  4. Review · secondary evidence

    [Facilitatory actions of the cognitive enhancer nefiracetam on neuronal Ca2+ channels and nicotinic ACh receptors: their intracellular signal transduction pathways].

    Yoshii M, Nishizaki T, Watabe S et al. · Nihon yakurigaku zasshi. Folia pharmacologica Japonica · 1998

    PMID 10190131 · DOI: 10.1254/fpj.112.supplement_41

Nefiracetam Powder supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Nefiracetam Powder for sale: compare prices, sizes and forms from every tracked supplier →

SupplierRecorded packagesExample source listing
Amino USAUSD10000mg Powder1 recorded offers10000mg Powder · $40.00Checked Oct 7, 2026Supplier listing

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles